Skip to main content

Theme news

Explore fairsonline.org coverage by editorial theme. Select a theme to see focused stories on innovation, strategy and market change.

Phase 3 KEYNOTE-B15 Puts KEYTRUDA-Padcev on Track to Redefine Perioperative Care in Muscle-Invasive Bladder Cancer

Image
Merck’s KEYTRUDA Plus Padcev Posts Phase 3 Perioperative Win in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

SHERIDAN, WYOMING - December 19, 2025 - Merck reported positive topline Phase 3 data showing its immunotherapy KEYTRUDA (pembrolizumab) combined with the antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) improved event-free survival, overall survival and pathologic complete response when used before and after surgery in cisplatin-eligible muscle-invasive bladder cancer (MIBC), setting up a potential shift in the perioperative standard of care.

Merck Secures Positive CHMP Opinion to Expand WINREVAIR Use in PAH, Potentially Extending Treatment to WHO FC IV in Europe

Image
Merck Secures Positive CHMP Opinion to Expand WINREVAIR Use in PAH, Potentially Extending Treatment to WHO FC IV in Europe

SHERIDAN, WYOMING - December 19, 2025 - Merck said the EMA's CHMP has recommended approval of an expanded European indication for WINREVAIR (sotatercept) in adults with pulmonary arterial hypertension (PAH), a move that-if confirmed by the European Commission-could broaden use to include WHO Functional Class (FC) IV patients and strengthen the product's positioning around morbidity and mortality benefit.

EXZOLT CATTLE-CA1 Wins FDA Conditional Approval, Expanding Options to Prevent and Treat New World Screwworm in Cattle

Image
FDA Conditionally Approves Merck Animal Health’s EXZOLT CATTLE-CA1 to Address New World Screwworm Risk in U.S. Beef and Heifer Herds

SHERIDAN, WYOMING - December 19, 2025 - Merck Animal Health says the U.S. Food and Drug Administration (FDA) has granted conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution), positioning the pour-on as a new systemic parasiticide option for U.S. beef operations and replacement dairy heifers facing New World screwworm (Cochliomyia hominivorax) larvae (myiasis) risk and cattle fever tick (Rhipicephalus microplus) pressure.

FDA Weighs National Priority Vouchers for Merck's Enlicitide and Sacituzumab Tirumotecan, Potentially Compressing Review Timelines

Image
FDA Weighs National Priority Vouchers for Merck’s Enlicitide and Sacituzumab Tirumotecan, Potentially Compressing Review Timelines

SHERIDAN, WYOMING - December 19, 2025 - The FDA is considering awarding Commissioner's National Priority Vouchers to two investigational Merck programs-PCSK9 pill enlicitide decanoate and antibody-drug conjugate sacituzumab tirumotecan-an early signal that the agency may be willing to accelerate reviews for high-impact products even before formal filings, according to a Reuters report.

A new FDA lever that can reshape launch timing
Commissioner's National Priority Vouchers are designed to shorten the FDA's regulatory review window from the typical 10-12 months to 1-2 months. For large pharma, that time compression can meaningfully shift competitive dynamics-pulling forward commercialization, altering payer and guideline sequencing, and increasing the urgency of manufacturing readiness, launch supply, and field execution.

Dentrix Ascend Adoption Surges as DSOs and Multi-Site Dental Groups Push Deeper Into Cloud and AI

Image
Henry Schein One's Dentrix Ascend Gains Momentum as 600 Practices Migrate in 2025 and DSO Adoption Accelerates

SHERIDAN, WYOMING - December 19, 2025 - Henry Schein One says adoption of its cloud-native Dentrix Ascend platform is accelerating as dental groups and DSOs move away from legacy practice management systems to standardize operations, reduce administrative friction, and embed AI into everyday workflows.

Cloud migration becomes a scaling decision, not an IT project
Across U.S. dentistry, consolidation and multi-location growth are forcing operators to treat practice management software as core infrastructure. Henry Schein One reported that nearly 600 practices migrated from alternative systems to Ascend over the past 12 months, adding to the broader Dentrix customer base of more than 48,000 practices using Dentrix technology for clinical, operational, and financial workflows. The company also said monthly Ascend installations more than doubled year over year as practices transitioned away from legacy setups.

MYTHIC Positions Integrated Counter-Drone Portfolio for Airports, Critical Infrastructure, and Event Security

Image
MYTHIC Positions Integrated Counter-Drone Portfolio for Airports, Critical Infrastructure, and Event Security

SHERIDAN, WYOMING - December 19, 2025 - MYTHIC, an overseas high-tech enterprise focused on anti-drone technologies, is expanding its profile as a low-altitude security provider by combining drone detection, intelligent identification, precise tracking, and efficient suppression into integrated defense systems designed for high-value, high-risk environments.

From point solutions to "intelligent airspace security barriers"
MYTHIC frames its core proposition as end-to-end protection against unauthorized UAV activity-built to perform in complex operational settings where disruption is not an option. The company says its solutions are deployed in airports, ports, petrochemical bases, hospitals, schools, luxury hotels, shopping malls, key public safety protection sites, and government office areas, reflecting buyer demand for layered protection that can be tuned to site constraints.

auto motor und sport Turns 80 With 232-Page XXL Issue, Setting 2026 Roadmap for Motor Presse Stuttgart

Image
auto motor und sport Turns 80 With 232-Page XXL Issue, Setting 2026 Roadmap for Motor Presse Stuttgart

SHERIDAN, WYOMING - December 18, 2025 - Motor Presse Stuttgart is kicking off a year-long anniversary cycle for its flagship automotive media brand auto motor und sport, marking 80 years of publishing with a premium-format XXL issue and a 2026 editorial program designed to deepen reach across print and digital channels.

An anniversary issue designed as a premium brand statement
Motor Presse Stuttgart is launching the jubilee year with an oversized special edition of auto motor und sport featuring a refined additional cover, larger format, and an expanded 232-page scope. The move signals a deliberate positioning strategy: in a fragmented media environment, special-interest publishers are increasingly using premium "event issues" to reinforce brand authority, extend dwell time, and create high-impact inventory for partners.

Citroën Brings ELO Concept, New C5 Aircross and Formula E Vision to Centre Stage at Brussels Motor Show 2026

Image
Citroën Bets on Compact EVs, Micro-Mobility and Formula E to Reignite Growth in Europe

SHERIDAN, WYOMING - December 18, 2025 - Citroën is using the 2026 Brussels Motor Show as a strategic showcase for its renewed electric portfolio and brand positioning, placing compact EV innovation, comfort-led SUVs and electric motorsport on the radar of European dealers, fleet buyers and mobility partners.

Brussels stand becomes a live lab for Citroën's electrification strategy

At the show, which opens to the public on 9 January 2026, Citroën is building a stand that mirrors its current transformation: colourful, modern and highly focused on accessible, electrified mobility. Alongside the world premiere of the ELO concept, visitors will see the new C5 Aircross as the brand's flagship SUV, the Ami in its new Dark Side edition, and a Formula E single-seater that signals Citroën's next era in electric motorsport.

For B2B stakeholders, the line-up illustrates how Citroën is repositioning its range around:

Citroën Names Aline Germain as Marketing Lead to Strengthen Global Brand Positioning From 2026

Image
Citroën Names Aline Germain as Marketing Lead to Strengthen Global Brand Positioning From 2026

SHERIDAN, WYOMING - December 18, 2025 - Citroën has appointed Aline Germain as the brand's new marketing lead, effective January 1, 2026, as the automaker continues to sharpen its global positioning across electric, hybrid, and mainstream mobility segments within the Stellantis portfolio.

Leadership change signals renewed focus on brand equity and go-to-market execution
Citroën said Germain will become responsible for Marketing Citroën from 1 january 2026, replacing Federico Goyret, who has been appointed to a position to be announced later. The company said Germain will report to Citroën Brand CEO Xavier Chardon, placing the role at the center of strategy-to-market coordination as Citroën competes for attention in a crowded European and global volume market.

Naples Boat Show Launches "Ready-to-Sea" Boutique Format at Marina di Stabia for March 2026 Debut

Image
Naples Boat Show Launches “Ready-to-Sea” Boutique Format at Marina di Stabia for March 2026 Debut

SHERIDAN, WYOMING - December 18, 2025 - A new B2B-focused nautical event, the Napoli Boat Show (NBS), will debut from March 18-22, 2026 at Marina di Stabia in Castellammare di Stabia, positioning itself as a "Boutique Boat Show" built around a simple commercial premise: every boat on display is ready to sail, and sea trials are the norm rather than the exception.

A "Ready-to-Sea" exhibition model built for sales conversations
Unlike traditional dockside showcases, NBS is designed to reverse exhibition logic by putting on-water testing at the center of the buying process. The show's proposition is that there is a material difference between viewing a vessel moored at the quay and experiencing it underway-especially in a setting that allows shipowners and professional buyers to evaluate handling, comfort, and performance in real conditions.

Advita Ortho Wins 2025 Innovation Award for Newton Balancing Technology in Total Knee Replacement

Image
Advita Ortho Wins 2025 Innovation Award for Newton Balancing Technology in Total Knee Replacement

SHERIDAN, WYOMING - December 16, 2025 - Advita Ortho has been recognized with an Innovation award in the 2025 Medical Device Network Excellence Awards for its Newton® Balancing Technology, highlighting the growing clinical and commercial demand for more data-driven, reproducible approaches to soft-tissue management in total knee replacement surgery.

Award recognition spotlights soft-tissue balancing as a key outcomes lever
While implant design and alignment remain central to knee arthroplasty performance, soft-tissue balancing is increasingly viewed as a differentiator in patient satisfaction and functional outcomes. Advita Ortho is positioning Newton as a method to bring greater consistency to what has often been a highly surgeon-dependent step-an area the company notes has historically contributed to dissatisfaction in a meaningful share of procedures.

HoldCo Urges Comerica Shareholders to Vote Against Fifth Third Deal, Citing Process Flaws, Valuation, and Litigation

Image
HoldCo Urges Comerica Shareholders to Vote Against Fifth Third Deal, Citing Process Flaws, Valuation, and Litigation

SHERIDAN, WYOMING - December 15, 2025 - HoldCo Asset Management says Comerica shareholders should vote against the proposed merger with Fifth Third at a special meeting scheduled for January 6, 2026, arguing the transaction undervalues Comerica and that rejecting the deal could improve shareholder outcomes with limited downside.

Activist investor challenges deal process and governance safeguards
HoldCo Asset Management, a Florida-based investment firm managing approximately $2.6 billion in regulatory assets under management, said it holds beneficial ownership of approximately 1.6% of Comerica's outstanding common stock and released a presentation titled "Why We Recommend Voting AGAINST The Proposed Merger and Our Litigation Update." The firm's case centers on how the transaction was negotiated and whether the board's process delivered maximum value for shareholders.

TuHURA Outlines Post-Financing Roadmap Across Phase 3 IFx-2.0, VISTA Antibody TBS-2025, and DOR-Targeting ADC Platform

Image
TuHURA Triggers CVR Share Release After REM-001 Trial Meets Primary Safety Endpoint in Metastatic Cutaneous Breast Cancer

SHERIDAN, WYOMING - December 15, 2025 - TuHURA Biosciences (NASDAQ: HURA) has provided a corporate update following a recent $15.6 million equity financing, detailing near-term milestones across its Phase 3 IFx-2.0 program in Merkel cell carcinoma, its VISTA-inhibiting antibody TBS-2025 in AML, and its Delta Opioid Receptor (DOR)-focused conjugate platform aimed at overcoming resistance to cancer immunotherapy.

Dubai Airshow 2025 Opens with COMAC C919 Making Middle East Debut as Chinese Aviation Presence Expands

Image
Dubai Airshow 2025 Opens with COMAC C919 Making Middle East Debut as Chinese Aviation Presence Expands

SHERIDAN, WYOMING - December 15, 2025 - Dubai Airshow 2025 opened at Dubai World Central with the Middle East debut of two of China's homegrown C919 aircraft, signaling a higher-profile push by Chinese aerospace players to showcase commercial, unmanned, and next-generation aviation technologies to global buyers.

C919 debut puts China's narrowbody on a new international stage
At the 19th edition of the Dubai Airshow, the appearance of the C919 marked its first showing in the Middle East, with a flight demonstration at the venue. The aircraft's presence matters beyond the air display: for airlines, lessors, MRO providers, and airport stakeholders, international showcases help shape early market perception around supply-chain maturity, support ecosystems, and longer-term export ambitions.

ARIDGE Unveils A868 Tilt-Rotor Hybrid Flying Car as Land Aircraft Carrier Factory Enters Trial Production

Image
ARIDGE Unveils A868 Tilt-Rotor Hybrid Flying Car as Land Aircraft Carrier Factory Enters Trial Production

SHERIDAN, WYOMING - December 15, 2025 - ARIDGE has introduced new details on its next-generation A868 flying car concept and confirmed fresh progress at its flying car manufacturing plant, as the company positions two flight systems to serve different segments of China's emerging low-altitude mobility market.

Two flight systems target distinct low-altitude travel needs
ARIDGE framed the low-altitude economy as the next major growth frontier following new energy vehicles, and outlined a dual-product strategy built around different operating missions. The company is developing:

ARIDGE Lands 600 Middle East Orders After Dubai Manned Flight, Positioning "Land Aircraft Carrier" for First International Market

Image
ARIDGE Lands 600 Middle East Orders After Dubai Manned Flight, Positioning "Land Aircraft Carrier" for First International Market

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT has completed a public manned flight of its modular flying car, the "Land Aircraft Carrier," in Dubai and signed purchase agreements totaling 600 flying cars across the Middle East, as the company accelerates overseas expansion and rebrands as ARIDGE.

Dubai manned flight pairs technology validation with commercial traction
The October 12 milestone combined a fully manned demonstration flight with what the company described as record-breaking regional demand, lifting total global orders to over 7,000. The event was witnessed by regional dignitaries, members of the local Chinese community, and more than 100 media outlets, signaling both regulatory interest and market visibility as the "low-altitude economy" shifts from concept showcases to procurement discussions.

UAE Grants XPENG AEROHT Special Manned Flight Permit, Advancing "Land Aircraft Carrier" eVTOL Testing in Ras Al Khaimah

Image
UAE Grants XPENG AEROHT Special Manned Flight Permit, Advancing “Land Aircraft Carrier” eVTOL Testing in Ras Al Khaimah

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT has secured a manned aircraft special flight permit from the UAE's General Civil Aviation Authority (GCAA) for its modular flying car "Land Aircraft Carrier" in Ras Al Khaimah, enabling manned flight tests across the country and marking a notable step in the overseas commercialization of China's low-altitude eVTOL technology.

Aviation permission becomes a market-entry signal for advanced air mobility
The permit, granted in Ras Al Khaimah, is positioned as the first such authorization obtained by a Chinese flying car company overseas. For B2B stakeholders-from mobility operators to public-sector agencies-regulatory access is often the gating factor that turns "future mobility" narratives into measurable pilots, procurement conversations, and infrastructure planning.

XPENG AEROHT Starts Trial Production at Flying Car Plant, Marking Shift Toward Scaled eVTOL Manufacturing

Image
XPENG AEROHT Starts Trial Production at Flying Car Plant, Marking Shift Toward Scaled eVTOL Manufacturing

SHERIDAN, WYOMING - December 15, 2025 - XPENG AEROHT, the flying car affiliate of Chinese EV maker XPENG, has begun trial production at what it describes as the world's first intelligent factory for mass-produced flying cars-an operational milestone as next-generation mobility moves from prototypes to industrial output.

Trial production signals a commercialization inflection point
The company started trial production on November 3, 2025, positioning the facility as a bridge between engineering validation and repeatable manufacturing. For the broader eVTOL and "low-altitude mobility" ecosystem, factory readiness matters because it shifts the discussion from flight demonstrations to supply chains, quality systems, and scalable assembly-areas that typically determine whether new vehicle categories can reach customers on schedule.